Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD16A | O95870 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 5/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | LIPC | P11150 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043178 | 0.81 | ABHD16A (0.59) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7660520 | 0.78 | MGLL (0.46) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7046507 | 0.78 | ABHD16A (0.56) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL2235103 | 0.77 | ABHD16A (0.74) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL6601668 | 0.77 | ABHD16A (0.54) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7048013 | 0.77 | ABHD16A (0.65) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7571649 | 0.76 | MGLL (0.72) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7650550 | 0.76 | MGLL (0.44) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL7045989 | 0.73 | MGLL (0.66) | ABHD16AMGLLFAAHLIPCLIPE | |
| SCHEMBL4404667 | 0.73 | ABHD16A (0.59) | ABHD16AMGLLFAAHLIPCLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | ABHD16A 1922/4885MGLL 1542/4885FAAH 46/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | ABHD16A 62/4885MGLL 10/4885FAAH 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.